Top Stories
The startup's AI-native technology platform is designed to speed up healthcare benefits for small businesses.
The findings could open up new ways to assess cardiometabolic health risks.
Counsel will join CMS's ACCESS model in early 2027 to provide care to Medicare patients with hypertension, obesity, hyperlipidaemia and prediabetes.
The funding follows an analysis of J&J's Phase III MARIPOSA study in which IPRO identified a treatment effect for Rybrevant 11 months before the trial’s primary progression-free survival readout.
Orbis' nGen platform combines generative AI and high-throughput synthesis to generate macrocycle compounds that are orally bioavailable.
Conference News
Data on >1,100 patients presented at the World Conference on Lung Cancer shows Signatera MRD status strongly predicted recurrence-free and overall survival in resected non-small cell lung cancer, with...
Interim data show high adherence and usability for remote, multimodal brain monitoring in borderline personality disorder and therapy-resistant depression, and a two-minute digital cognitive task perf...
ZEISS' new multimodal solution combines automated OCT and fundus imaging to support simplified and efficient retinal assessment across a broader range of eye care practices.JENA, Germany, Sept. 17, 20...
These findings support the potential of MammaTyper® LRP as a locally available low cost molecular pre-screen for identifying patients having an Oncotype DX® RS ≤25 who are at low recurrence risk.”— Ri...
DALLAS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more...
